Mygenia ctDNA - Early Cancer Screening

What is Cancer?

Cancer is a type of genetic disease that is often caused by accumulated DNA mutation. It normally takes a few years and even a decade of time to develop a malignant tumor from DNA mutation.

The incidence and mortality of cancer are on the rise
- Cancer has become the top killer in both Hong Kong and Mainland China
 
Affecting every one of us
- Nearly everyone has heard of real cancer cases within their social circles
 
Suffering cancer was gradually younger
China accounts for 1/4 of the global deaths of young cancer patients
 
Most patients are already in the middle and late stages of cancer when they are diagnosed
- Most early-stage cancer patients have a five-year survival rate of over 90%

 

A breakthrough in ctDNA technology

Currently, there is a growing trend in early cancer screening by DNA examination worldwide. With the advances in sequencing technology, scientists have stepped forwards and demonstrated that ctDNA technology is applicable in most cancer types at both early and advanced stages.  

What is ctDNA? A non-invasive cancer biomarker

Circulating Tumor DNA (ctDNA) is fragmented DNA that originates from cancerous cells and tumors. As a tumor grows, cancerous cells release these small pieces of DNA into the bloodstream both actively and passively. Owing to its high specificity to tumor, ctDNA is regarded as an effective yet non-invasive cancer biomarker. 

Cure for Cancer, Closer than You Think

ctDNA technology, as a non-invasive method for cancer screening, presents a low-risk yet effective assessment complementing traditional biopsies. We believe ctDNA technology could help monitor your health progressively and protect you from cancer.  

Catch cancer way before normal body check-up

As we all know, PET-CT could detect the presence of tumor. Yet, ctDNA technology leaps forwards by detecting the earliest alternation of DNA sequences in cancerous cells. It allows us to take action before tumor development and increases the chance of survival. 

ctDNA screening procedure

Test Specifications

Test Code
Methodology
Specimen Requirements
Turnaround Time
OCT
Next generation sequencing (NGS)
20ml Streck Blood
6 weeks

Advantages of MYGENIA® ctDNA - Early Cancer screening

  • Target gene is sequenced by advanced NGS technology
  • 56 genes are sequenced and examined
  • Average read depth reaches 20,000 reads/gene
  • High sensitivity - mutation with occurance as low as 0.25% could be detected
  • High specificity - specificity exceeds 90%

MYGENIA® ctDNA - Early Cancer Screening

Circulating tumour DNA (ctDNA) Genetic Test

A single test estimating your risk of common cancers 

Healthy individuals at all ages
  • Healthy individuals at all ages
  • Unhealthy lifestyle
  • Smoking, excessive drinking or unbalanced diet
  • Overweight, lack of exercise
  • Individual with chronic disease or poor immunity
  • Concerns about getting malignant tumor
  • Individuals with family history of cancer
  • Multiple family members with same cancer type

How to get started

Our tests must be ordered by a doctor. Ask your doctor if a Mygenia test is right for you. We can help you find a doctor if you don’t have one.

I have a doctor
References
  1. reference 1
  2. reference 2
  3. reference 3